An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
Epistemonikos ID: 3e6fac346f9ffaa691a1043c6379247dbea198a5
First added on: May 15, 2024